D7777
Dulbecco′s Modified Eagle′s Medium - high glucose
With 4500 mg/L glucose, L-glutamine, and sodium pyruvate, without sodium bicarbonate, powder, suitable for cell culture
Synonym(s):
DME, DMEM
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352207
NACRES:
NA.75
Recommended Products
Quality Level
form
powder
technique(s)
cell culture | mammalian: suitable
components
glucose: high
sodium pyruvate: yes
NaHCO3: no
HEPES: no
phenol red: yes
L-glutamine: yes
shipped in
ambient
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
Application
Dulbecco′s Modified Eagle′s Medium (DMEM) is a modification of Basal Medium Eagle (BME) that contains four-fold concentrations of the amino acids and vitamins. The original formulation contained 1000 mg/L of glucose and was used to culture embryonic mouse cells. Since then, it has been modified in several ways to support primary cultures of mouse and chicken cells, as well as a variety of normal and transformed cells. Each of these media offers a different combination of L-glutamine and sodium pyruvate. Additionally, the glucose levels have been raised to 4500 mg/L, contributing to the name "DMEM/High".
Quantity
Formulated to contain 13.5 grams of powder per liter of medium.
Reconstitution
Supplement with 3.7 g/L sodium bicarbonate
also commonly purchased with this product
Product No.
Description
Pricing
related product
Product No.
Description
Pricing
supplement
Product No.
Description
Pricing
Storage Class Code
13 - Non Combustible Solids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Megan E Muroski et al.
Journal of the American Chemical Society, 136(42), 14763-14771 (2014-09-10)
Mesenchymal stem cells (MSC) have been identified as having great potential as autologous cell therapeutics to treat traumatic brain injury and spinal injury as well as neuronal and cardiac ischemic events. All future clinical applications of MSC cell therapies must
Jie Wang et al.
Molecular medicine reports, 22(2), 1111-1118 (2020-07-07)
Neuromyelitis optica (NMO) is a severe neurological demyelinating autoimmune disease that affects the optic nerves and spinal cord. There is currently no effective cure or therapy. Aquaporin‑4 (AQP4) is a known target of the autoimmune antibody NMO‑IgG. Therefore, binding of
Emilia Galli et al.
Cell transplantation, 28(4), 413-424 (2019-03-08)
Cerebral dopamine neurotrophic factor (CDNF) shows beneficial effects in rodent models of Parkinson's and Alzheimer's disease. The brain is a challenging target for protein therapy due to its exclusive blood-brain barrier. Hence, the therapeutic protein should be delivered directly to
Otávio Valério de Carvalho et al.
Virology journal, 14(1), 124-124 (2017-06-28)
Canine distemper (CD) is a widespread infectious disease that can severely impact a variety of species in the order Carnivora, as well as non-carnivore species such as non-human primates. Despite large-scale vaccination campaigns, several fatal outbreaks have been reported in
Maria H Jäntti et al.
FEBS open bio, 8(5), 817-828 (2018-05-11)
Prostate cancer is one of the most common cancers in men. Although it has a relatively high 5-year survival rate, development of resistance to standard androgen-deprivation therapy is a significant clinical problem. Therefore, novel therapeutic strategies are urgently needed. The
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service